FIP TREATMENT IN THE USA:
Compounded GS-441524 tablets are now available!

This discussion provides US clinicians with the most up-to-date information on treatment and monitoring protocols for FIP that are being routinely utilized in Australia, the UK and Japan. This webinar aims to bring a very practical focus to ensure general practitioners feel confident to start readily treating these cases.

1. Participants will receive updates on current antiviral medications being utilised for treatment of feline infectious peritonitis.
2. Participants will gain information on how to optimise monitoring, with expected times to normalization for key clinicopathologic parameters and when to consider dose adjustments.
3. Key take-home messages around “what to avoid” when managing FIP cases will also be discussed.
4. This session will conclude with discussion of other antivirals to consider for combined or alternative treatment with refractory cases.

Dr. Sally Coggins graduated from The University of Sydney, Australia in 2007 and has been a feline-only clinician since 2010. She attained memberships in feline medicine with the ANZCVS in 2012, was a director at The Cat Clinic Melbourne, an examiner with the ANZCVS, and tutors for the Centre for Veterinary Education. Since 2020, Sally has been completing a PhD investigating antiviral therapies for FIP, where she conducted a national prospective study utilizing remdesivir and GS-441524; characterized the in vitro and in vivo pharmacokinetics of remdesivir in cats with FIP; co-authored a retrospective collaborative study assessing treatment outcomes of 307 cats treated with remdesivir and GS-441524 and has ongoing research collaboration with the US, UK, Germany and New Zealand. Sally also continues to practice clinically one day a week at Evervet in Melbourne, Australia.